Brokers Offer Predictions for CADL FY2027 Earnings

Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Equities researchers at Brookline Capital Markets issued their FY2027 earnings estimates for shares of Candel Therapeutics in a research report issued to clients and investors on Friday, November 13th. Brookline Capital Markets analyst K. Dolliver anticipates that the company will earn ($1.52) per share for the year. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.22) per share.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06.

Several other research firms have also recently weighed in on CADL. Stifel Nicolaus reduced their target price on shares of Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, November 13th. Wall Street Zen downgraded Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 16th. Canaccord Genuity Group lowered their price target on Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating on the stock in a research note on Friday, November 13th. HC Wainwright lowered their price target on Candel Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, November 13th. Finally, Bank of America raised Candel Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $12.00 to $18.00 in a report on Monday, September 21st. Nine research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.29.

Get Our Latest Research Report on Candel Therapeutics

Candel Therapeutics Stock Performance

NASDAQ CADL opened at $5.40 on Monday. The company’s fifty day moving average is $9.47 and its two-hundred day moving average is $8.39. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00. The company has a debt-to-equity ratio of 0.37, a current ratio of 7.57 and a quick ratio of 7.57. The firm has a market capitalization of $423.63 million, a price-to-earnings ratio of -3.65 and a beta of -0.27.

Institutional Investors Weigh In On Candel Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of CADL. BlackRock Inc. bought a new position in shares of Candel Therapeutics during the 2nd quarter worth about $51,181,000. Bank of America Corp DE acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $2,873,000. Wellington Management Group LLP acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $2,119,000. Bank of New York Mellon Corp acquired a new stake in shares of Candel Therapeutics during the 2nd quarter valued at about $1,975,000. Finally, Janus Henderson Group PLC bought a new stake in Candel Therapeutics in the first quarter valued at about $845,000. Institutional investors own 13.93% of the company’s stock.

Key Stories Impacting Candel Therapeutics

Here are a few of the latest stories about CADL:

  • Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
  • Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
  • Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Recommended Stories

Earnings History and Estimates for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.